{"id":5686,"date":"2006-03-25T08:33:22","date_gmt":"2006-03-25T08:33:22","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=5686"},"modified":"2013-12-07T07:50:46","modified_gmt":"2013-12-07T07:50:46","slug":"simplification-to-atazanavirritonavir-monotherapy","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/5686","title":{"rendered":"Simplification to atazanavir\/ritonavir monotherapy"},"content":{"rendered":"<p><strong>POSTSCRIPT NOTE:\u00a0<\/strong><strong>Please note that subsequent studies have raised serious cautions against the strategy of boosted atazanavir monotherapy and that this is no longer recommended even within a study setting.<\/strong> [2]<\/p>\n<p>&#8230;&#8230;.<\/p>\n<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Susan Swindells and colleagues from University of Nebraska presented results from a study that switched 36 patients who had suppressed viral load &lt;50 copies\/mL for at least one year on their first PI-based triple therapy (with 2 RTIs), to atazanavir\/ritonavir maintenance therapy.<\/strong> [1]<strong> <\/strong><\/p>\n<p>The primary endpoint of the study was viral suppression &lt;200 copies\/mL at 24 weeks after stopping the RTIs.<\/p>\n<p>The median follow-up was 194 days (range 84 to 345). Two patients discontinued the study before switching (one withdrew consent and one had viral rebound &gt;50 copies\/mL. Of the 34 remaining patients, three experienced viral rebound at 12, 14 and 24 weeks to 1285, 4730, and 28,397 copies\/mL respectively. Two of these patients had no detectable levels of atazanavir at failure, the third resuppressed to &lt;50 copies\/mL while on ATZ\/r alone. PI resistance was not detected at failure in these three patients. There were no treatment discontinuations for adverse events after simplification.<\/p>\n<p>The observed virologic success 24 weeks after simplification was 91% (lower 90% CI limit = 85%).<\/p>\n<p><strong>POSTSCRIPT COMMENT<\/strong><\/p>\n<p><strong>Please note that subsequent studies have raised serious cautions against the strategy of boosted atazanavir monotherapy and that this is no longer recommended even within a study setting.<\/strong> [2]<\/p>\n<p>References<\/p>\n<ol>\n<li>Swindells S, Wilkin T, DiRienzo G et al. A prospective, open-label, pilot trial of regimen simplification to atazanavir\/ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression (ACTG 5201). 13th Conference on Retroviruses and Opportunistic Infections, 5- February 2006, Denver. Oral late breaker abstract 108LB.<br \/>\n<a href=\"http:\/\/www.retroconference.org\/2006\/Abstracts\/27942.HTM\">http:\/\/www.retroconference.org\/2006\/Abstracts\/27942.HTM<\/a><\/li>\n<li>Karlstrom et al. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):417-22.<br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17159658\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17159658<\/a> Full text on <a href=\"http:\/\/www.medscape.com\/viewarticle\/554859\">Medscape<\/a>.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>POSTSCRIPT NOTE:\u00a0Please note that subsequent studies have raised serious cautions against the strategy of boosted atazanavir monotherapy and that this is no longer recommended even within a study setting. [2] &#8230;&#8230;. Simon Collins, HIV i-Base Susan Swindells and colleagues from &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,41],"tags":[60],"class_list":["post-5686","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-treatment-strategies","tag-croi-2006"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=5686"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5686\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=5686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=5686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=5686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}